FMP
XTL Biopharmaceuticals Ltd.
XTLB
NASDAQ
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
1.3 USD
-0.01 (-0.769%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel...
CIK
0001023549
ISIN
US98386D3070
CUSIP
98386D307
Address
5 Badner Street
Phone
972 3 611 6600
Country
IL
Employee
8
IPO Date
Sep 1, 2005
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
XTLB Financial Summary
CIK
0001023549
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
98386D307
ISIN
US98386D3070
Country
IL
Price
1.3
Beta
1.01
Volume Avg.
5.2k
Market Cap
11.46M
Shares
-
52-Week
0.92-3.15
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-6.5
P/B
-
Website
https://www.xtlbio.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest XTLB News
It looks like there's no news available.
